FDA news on Enbrel, generic Oxistat cream top dermatology reads for week

The FDA’s acceptance to review a supplemental biologics license application for Enbrel to treat pediatric patients with psoriasis and its approval of the first generic of Oxistat cream, 1% was among the most-read article of the past week on Healio.com/Dermatology.

Other widely read articles included a blog post by Kimberly Butterwick, MD, on cosmetic pearls from the American Academy of Dermatology Annual Meeting:

BLOG: Cosmetic pearls from the AAD annual meeting

Kimberly J. Butterwick, MD, shares cosmetic pearls in her blog post for Healio.com/Dermatology.

Kimberly J. Butterwick

Among the highlights from the American Academy of Dermatology Annual Meeting was a demonstration of a new lifting technique with poly-l-lactic acid absorbable sutures called the Sinclair Silhouette thread lift. Read more

FDA accepts supplemental BLA for Enbrel for treating pediatric patients with psoriasis

Amgen announced in a press release that the FDA has accepted to review its supplemental biologics license application for expanding the use of Enbrel to treat pediatric patients with chronic severe plaque psoriasis.

Results from a phase 3, 1-year study and a 5-year, open-label extension study to measure the safety and efficacy of Enbrel (etanercept) as treatment for pediatric patients with moderate-to-severe plaque psoriasis were used in the supplemental biologics license application (BLA), according to the release. Read more

FDA approves first generic of Oxistat cream, 1% for athlete's foot, jock itch and ringworm

The FDA announced the approval for the first generic of Oxistat cream, 1% for treating athlete’s foot, jock itch, ringworm and tinea versicolor due to Malassezia furfur.

Common side effects of oxiconazole nitrate cream, 1% reported in clinical trials included pruritus, burning, irritation and allergic contact dermatitis, folliculitis, erythema, and papules, fissure, maceration, rash, stinging, and nodules, according to a drug information update from the FDA. Read more

VIDEO: Amy J. McMichael, MD, reviews new topical treatment for hair loss

WASHINGTON – In a video perspective, Amy J. McMichael, MD, discusses research she reviewed on qilib, a new over-the-counter topical treatment for hair loss.

The qilib hair care line (Galderma Laboratories) uses a solution formulated with botanicals, including an onion extract as its active ingredient, in conjunction with 2% minoxidil for women and 5% minoxidil for men. Watch video

VIDEO: Tina Alster, MD, compares Kybella to CoolMini for treating submental fullness

WASHINGTON — In a video perspective from the American Academy of Dermatology Annual Meeting, Tina Alster, MD, compares two new treatments for submental fullness.

Alster, director of the Washington Institute of Dermatologic Laser Surgery and clinical professor of dermatology, Georgetown University, Washington, D.C., reported on results and best uses for Kybella (deoxycholic acid, Allergan) versus the CoolMini, which utilizes CoolSculpting technology (cyrolipolysis, Zeltique). Watch video